Riskpilot← Back to searchSign inGet full accessNORDJYSK HELSESTUDIO ApS
APSActiveCVR 73871417Uldalsvej 1Day spa, sauna and steam bath activities · NACE 9623Est. 19831 employees
Revenue 2025
DKK -168K
-16% vs 2024
EBITDA margin
117.8%
+3% vs 2024
Equity ratio
-26210.6%
Financial strength
Net profit 2025
DKK -235K
+8% vs 2024
| Revenue | DKK -168K | -16% |
| EBITDA | DKK -198K | +3% |
| Net profit | DKK -235K | +8% |
| Total assets | DKK 6K | -59% |
| Equity | DKK -1,6M | -18% |
| Employees | 1 | — |
Legal name
NORDJYSK HELSESTUDIO ApS
CVR number
73871417
Legal form
Anpartsselskab
NACE code
9623 · Day spa, sauna and steam bath activities
Founded
9. november 1983
Share capital
DKK 200.000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-04-30
Financial year
January – December
Signatory rights
Selskabet tegnes af to medlemmer af bestyrelsen i forening eller af et medlem af bestyrelsen i forening med en direktør
Company purpose
Selskabets formål er at drive helse- og solcenter
Address
Uldalsvej 1
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 | -58 | -153 | -201 | -168 |
| Staff expenses | -15 | -0 | -0 | -0 | -30 |
| EBITDA | -14 | -58 | -153 | -204 | -198 |
| Depreciation & amort. | -34 | -23 | -0 | -4 | -15 |
| EBIT | -48 | -81 | -153 | -208 | -213 |
| Net financials | 24 | -50 | -31 | -48 | -22 |
| Profit before tax | -24 | -131 | -184 | -256 | -235 |
| Tax | -0 | -0 | -0 | -0 | -0 |
| Net profit | -24 | -131 | -184 | -256 | -235 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 180 | 33 | 14 | 14 | 6 |
| Equity | -766 | -897 | -1.082 | -1.338 | -1.573 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 946 | 931 | 1.096 | 1.352 | 1.579 |
| Total debt | 946 | 931 | 1.096 | 1.352 | 1.579 |
EBITDA margin
-19820900.0%
This company
15.8%
Market median
-125448834% vs market
20212025
Equity ratio
-26210.6%
This company
38.2%
Market median
-68714% vs market
20212025
Return on equity
-23491500.0%
This company
18.4%
Market median
-127671296% vs market
20212025
Net profit margin
-23491500.0%
This company
8.1%
Market median
-290018619% vs market
20212025
Asset turnover
-28.03×
This company
1.12×
Market median
-2603% vs market
20212025
Debt / equity
1.00×
This company
0.62×
Market median
-61% vs market
20212025
- Annual report 2025Filed via CVR / Virk · Period 2024-05-01 – 2025-04-30
- Annual report 2024Filed via CVR / Virk · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via CVR / Virk · Period 2022-05-01 – 2023-04-30
- Annual report 2022Filed via CVR / Virk · Period 2021-05-01 – 2022-04-30
- Annual report 2021Filed via CVR / Virk · Period 2020-05-01 – 2021-04-30
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
IJ Audit | Audit | 1983 – 2006 |
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
| Board of Directors | 1983 – 1990 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 66.67–89.99% | 66.67–89.99% | 1985 | |
| Individual | 10–14.99% | 10–14.99% | 1985 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of NORDJYSK HELSESTUDIO ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ingo Jespersen | Audit | 0 companies |
| Michael Schultz | Board of Directors | 0 companies |